Wells Fargo lifts target for Elevance Health stock to USD 492.00

Published on 10/27/2026 at 18:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter revenue rose 0.70 percent to USD 50.40 billion. Elevance Health stock costs EUR 377.80 on October 27, 2026.

Wells Fargo target raised

Wells Fargo raised its Elevance Health target from USD 473.00 to USD 492.00 on October 27, 2026.
Third-quarter operating revenue increased 0.70 percent to USD 50.40 billion.
Elevance Health stock costs EUR 377.80 at Lang & Schwarz on October 27, 2026 at 6:08 p.m. CEST.
The fourth-quarter dividend is USD 1.72 per share, payable on December 18, 2026.

Elevance Health, US0367521038, Illustration mit AI erstellt.

On October 27, 2026, Wells Fargo raised its Elevance Health target from USD 473.00 to USD 492.00 while keeping an Overweight rating, according to Investing.com. Against the USD 421.11 NYSE quote at 1:11 p.m. ET, the new target is 16.84 percent above the price. At Lang & Schwarz, the stock was trading at EUR 377.80 on October 27, 2026 at 6:08 p.m. CEST.

Revenue growth stays modest

Elevance Health reported operating revenue of USD 50.40 billion for the third quarter of 2026, up 0.70 percent from the prior-year quarter, according to its Elevance Health release dated October 21, 2026. Adjusted diluted earnings per share reached USD 6.99, while the benefit expense ratio improved to 90.60 percent.

The operating mix was uneven. Health Benefits revenue rose 3.00 percent year over year to USD 43.40 billion, while Carelon revenue increased 5.00 percent to USD 19.30 billion. Medical membership declined by 487,000 to 44.90 million as of September 30, 2026.

What supports the higher target?

Wells Fargo cited constructive third-quarter performance in Medicaid and health insurance exchanges. Its 2026 earnings-per-share estimate increased by USD 2.00 to USD 30.28, which the firm placed 4.50 percent above a USD 29.33 consensus estimate, according to Investing.com. The report also identified one-time valuation benefits and tax effects within the estimate increase.

Dividend date is December 18

Elevance Health declared a fourth-quarter dividend of USD 1.72 per share on October 20, 2026. The dividend is payable on December 18, 2026, to shareholders of record at the close of business on December 4, 2026, according to the company's October 21 release.

Valuation beside healthcare peers

Elevance Health had a price-to-earnings ratio of 17.96 and a market capitalization of USD 91.3 billion as of October 27, 2026. Humana traded at a price-to-earnings ratio of 39.14 with a market capitalization of USD 49.7 billion, while Centene traded at 23.74 times earnings with a market capitalization of USD 34.3 billion on the same date.

Stock price and investor perspective

The higher Wells Fargo target adds a fresh valuation reference after the third-quarter figures, but the membership decline remains a measurable operating counterpoint. The updated target therefore rests on stronger earnings expectations alongside continued execution in Medicaid, exchanges and Carelon.

The stock was trading at EUR 377.80 at Lang & Schwarz on October 27, 2026 at 6:08 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Elevance Health stock.